Business Description
Septerna is a clinical-stage biotech company focused on developing oral pill-based medicines that work through a class of cell receptors known as GPCRs. Its current pipeline targets conditions such as hypoparathyroidism, chronic hives, Graves' disease, and thyroid eye disease, with additional research underway in areas like heart health, women's health, and neurology. The company also holds a partnership with Novo Nordisk to discover and bring to market oral treatments for metabolic diseases. Founded in 2019 and based in South San Francisco, California, Septerna operates across multiple therapeutic areas with the goal of addressing diseases that currently lack effective oral treatment options.
